Phase IIB Study of Recombinant Novel Coronavirus Vaccine (FH-63)
An Open-label Clinical Trial Phase IIB to Evaluate the Immunogenicity and Safety of Recombinant Novel Coronavirus Vaccine in Participants Aged 18 Years and Above That Previously Received One Dose of Sputnik V
Sponsor: CanSino Biologics Inc.
Listed as NCT05293223, this PHASE2 trial focuses on COVID-19 Vaccine and remains completed. Sponsored by CanSino Biologics Inc., it has been updated 8 times since 2021, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Jul 2025 — Sep 2025 [monthly]
Completed PHASE2
Status: Unknown → Completed
-
Apr 2025 — Jul 2025 [monthly]
Unknown PHASE2
Status: Active Not Recruiting → Unknown
-
Sep 2024 — Apr 2025 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
▶ Show 3 earlier versions
-
Apr 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
Oct 2022 — Apr 2023 [monthly]
Active Not Recruiting PHASE2
-
Apr 2022 — Oct 2022 [monthly]
Active Not Recruiting PHASE2
First recorded
Oct 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- CanSino Biologics Inc.
- Dalhousie University
- Fundación Huésped
For direct contact, visit the study record on ClinicalTrials.gov .